Decitabine improves patient outcomes in myelodysplastic syndromes

Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.

[1]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[2]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[3]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[4]  E. Estey,et al.  Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). , 2003, Blood.

[5]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[6]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[7]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[9]  E. Estey,et al.  Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. , 1997, Blood.

[10]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[11]  G. Blandino,et al.  Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. , 2002, Blood.

[12]  J. Issa,et al.  Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules , 2005 .

[13]  J. Issa,et al.  Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.

[14]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[15]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[16]  M. Voso,et al.  Background and Objectives. Methylation of DNA is a , 2022 .

[17]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[19]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[20]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[21]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[22]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[23]  J. Issa,et al.  First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). , 2004 .

[24]  P. Néve,et al.  Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome , 1997, Leukemia.